Ontology highlight
ABSTRACT:
SUBMITTER: Pilla Reddy V
PROVIDER: S-EPMC6585620 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
Clinical pharmacology and therapeutics 20180809 1
We report physiologically based pharmacokinetic-modeling analyses to determine olaparib (tablet or capsule) drug-drug interactions (DDIs). Verified DDI simulations provided dose recommendations for olaparib coadministration with clinically relevant CYP3A4 modulators to eliminate potential risk to patient safety or olaparib efficacy. When olaparib is given with strong/moderate CYP3A inhibitors, the dose should be reduced to 100/150 mg b.i.d. (tablet), and 150/200 mg b.i.d. (capsule). Olaparib adm ...[more]